Aurinia Pharmaceuticals (AUPH) Depreciation & Amortization (CF) (2020 - 2026)

Aurinia Pharmaceuticals has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 0.82% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $19.4 million (changed 0.23% YoY), and the FY2025 full-year result was $19.4 million, changed 0.02% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $4.8 million, down from $4.9 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $5.3 million in Q3 2023, with the low at -$6.1 million in Q4 2023.
• Historically, Depreciation & Amortization (CF) has averaged $2.6 million across 5 years, with a median of $4.8 million in 2024.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) slumped 223.16% — and 2024, when it jumped 576.01%.
• Aurinia Pharmaceuticals' Depreciation & Amortization (CF) stood at -$1.9 million in 2022, then tumbled by 223.16% to -$6.1 million in 2023, then jumped by 179.73% to $4.9 million in 2024, then rose by 0.04% to $4.9 million in 2025, then retreated by 0.99% to $4.8 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $4.8 million (Q1 2026), $4.9 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.